08:53:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-28 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-22 Kvartalsrapport 2024-Q1
2024-04-25 X-dag ordinarie utdelning SCOL 0.00 SEK
2024-04-24 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-04-27 X-dag ordinarie utdelning SCOL 0.00 SEK
2023-04-26 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-28 X-dag ordinarie utdelning SCOL 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-11-17 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 X-dag ordinarie utdelning SCOL 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning SCOL 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-21 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-11 Extra Bolagsstämma 2019
2019-05-31 X-dag ordinarie utdelning SCOL 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-27 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-11-18 Kvartalsrapport 2018-Q3


ListaFirst North Stockholm
Scandion Oncology är verksamt inom bioteknik. Bolaget är fokuserat inom utveckling av läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier använts inom olika standardcancerbehandlingar. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn, Danmark.
2023-11-22 08:30:00

Scandion Oncology (Scandion) today announces its interim report for Q3 2023. The following is taken from the report.

Francois Martelet, CEO:

“We have completed patient enrollment to the CORIST part 3 trial and are very encouraged by new data from part 2 of the trial showing very positive results on overall survival and several patients with tumor reductions”

Key Figures & Highlights

TDKKQ3 2023Q1-Q3 2023Q3 2022Q1-Q3 2022FY 2022

Operating loss-10,910-34,202-23,626-64,778-80,166

Net finance income/cost355487-1,447-1,735-2,034

Loss before tax-10,555-33,715-25,073-66,513-82,200

Net loss-10,153-28,215-25,073-61,013-76,700

Total assets50,83250,832106,474106,47489,401

Cash Position36,33036,33091,36291,36277,605

Total equity42,11142,11185,61285,61270,327

Equity ratio83%83%80%80%79%

Earnings per share (EPS)-0.25-0.69-0.62-1.50-1.88

Shares outstanding, ending40,706,97240,706,97240,706,97240,706,97240,706,972

Highlights during Q3 2023

  • On July 18, The European Patent Office announced intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101. If granted, the patent will cover the commercial solid form of SCO-101 until at least 2042.
  • On August 17, Data from PANTAX trial to be presented at ESMO Congress 2023.
  • On September 12, Scandion Oncology appoints Lars Damstrup, MD, PHD, as new Chief Medical Officer.

Highlights after the end of the period

  • On October 16, Phase Ib PANTAX Trial is successfully completed and establishes the Maximal Tolerated Dose with positive Safety Profile and Pharmacokinetic data.
  • On November 21 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive Overall Survival median of 10.4 months. A subset of patients (17 out of 25) had OS median of 13.4 months. Historical median OS data for the same patient population treated with placebo or best supportive care have been reported in the range of 5-7 months.

The interim report Q3 2023 is available on the Company's website: www.scandiononcology.com.

Audiocast today, November 22 at 10:00 am CET

Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

Access to the event can be obtained as follows:

LIVE access on Wednesday November 22, 2023, at 10:00 CET: https://financialhearings.com/event/46156

REPLAY access
Webcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com

The information was provided by the contact person above for publication on November 22, 2023, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.